PH12014501890B1 - Solid oral formulations and crystalline forms of an inhibitor of apoptosis protein - Google Patents
Solid oral formulations and crystalline forms of an inhibitor of apoptosis proteinInfo
- Publication number
- PH12014501890B1 PH12014501890B1 PH12014501890A PH12014501890A PH12014501890B1 PH 12014501890 B1 PH12014501890 B1 PH 12014501890B1 PH 12014501890 A PH12014501890 A PH 12014501890A PH 12014501890 A PH12014501890 A PH 12014501890A PH 12014501890 B1 PH12014501890 B1 PH 12014501890B1
- Authority
- PH
- Philippines
- Prior art keywords
- solid oral
- inhibitor
- crystalline forms
- oral formulations
- apoptosis protein
- Prior art date
Links
- 238000009472 formulation Methods 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 239000007787 solid Substances 0.000 title abstract 2
- 108091007065 BIRCs Proteins 0.000 title 1
- 102000055031 Inhibitor of Apoptosis Proteins Human genes 0.000 title 1
- UFPFGVNKHCLJJO-SSKFGXFMSA-N (2s)-n-[(1s)-1-cyclohexyl-2-[(2s)-2-[4-(4-fluorobenzoyl)-1,3-thiazol-2-yl]pyrrolidin-1-yl]-2-oxoethyl]-2-(methylamino)propanamide Chemical compound C1([C@H](NC(=O)[C@H](C)NC)C(=O)N2[C@@H](CCC2)C=2SC=C(N=2)C(=O)C=2C=CC(F)=CC=2)CCCCC1 UFPFGVNKHCLJJO-SSKFGXFMSA-N 0.000 abstract 2
- 150000004677 hydrates Chemical class 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- -1 hydrates) thereof Chemical class 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US27405109P | 2009-08-12 | 2009-08-12 | |
| PCT/EP2010/061679 WO2011018474A1 (en) | 2009-08-12 | 2010-08-11 | Solid oral formulations and crystalline forms of an inhibitor of apoptosis protein |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| PH12014501890A1 PH12014501890A1 (en) | 2015-09-14 |
| PH12014501890B1 true PH12014501890B1 (en) | 2015-09-14 |
Family
ID=42937834
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PH12014501890A PH12014501890B1 (en) | 2009-08-12 | 2014-08-20 | Solid oral formulations and crystalline forms of an inhibitor of apoptosis protein |
Country Status (24)
| Country | Link |
|---|---|
| US (4) | US8623385B2 (enExample) |
| EP (1) | EP2464644A1 (enExample) |
| JP (3) | JP2013501751A (enExample) |
| KR (2) | KR20180020315A (enExample) |
| CN (2) | CN102471331B (enExample) |
| AR (1) | AR077869A1 (enExample) |
| AU (4) | AU2010283748A1 (enExample) |
| BR (1) | BR112012003118A2 (enExample) |
| CA (1) | CA2769616A1 (enExample) |
| CL (1) | CL2012000349A1 (enExample) |
| CO (1) | CO6612189A2 (enExample) |
| IL (1) | IL217760A0 (enExample) |
| IN (1) | IN2012DN00858A (enExample) |
| MA (1) | MA33511B1 (enExample) |
| MX (2) | MX351274B (enExample) |
| MY (1) | MY160475A (enExample) |
| PE (2) | PE20170777A1 (enExample) |
| PH (1) | PH12014501890B1 (enExample) |
| RU (1) | RU2671196C1 (enExample) |
| SG (1) | SG177713A1 (enExample) |
| TN (1) | TN2012000026A1 (enExample) |
| TW (1) | TWI607006B (enExample) |
| WO (1) | WO2011018474A1 (enExample) |
| ZA (1) | ZA201200390B (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3020792A1 (en) | 2016-04-20 | 2017-10-26 | Glaxosmithkline Intellectual Property Development Limited | Conjugates comprising ripk2 inhibitors |
| CN108484640B (zh) * | 2018-05-22 | 2020-09-15 | 南京华威医药科技集团有限公司 | 一种抗肿瘤的细胞凋亡蛋白抑制剂 |
| IL280880B2 (en) | 2018-08-27 | 2025-04-01 | Regeneron Pharma | Using Raman Spectroscopy in Downstream Purification |
| HUP2200468A1 (hu) | 2020-04-29 | 2023-03-28 | X Chem Zrt | IAP antagonisták és gyógyászati alkalmazásuk |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030124028A1 (en) * | 2001-08-10 | 2003-07-03 | Carlson Eric D. | Apparatuses and methods for creating and testing pre-formulations and systems for same |
| US20060128632A1 (en) | 2002-07-02 | 2006-06-15 | Sharma Sushil K | Peptide inhibitors of smac protein binding to inhibitor of apoptosis proteins (iap) |
| WO2005097791A1 (en) * | 2004-04-07 | 2005-10-20 | Novartis Ag | Inhibitors of iap |
| EA019420B1 (ru) | 2004-12-20 | 2014-03-31 | Дженентех, Инк. | Пирролидиновые ингибиторы иап (ингибиторов апоптоза) |
| PE20110224A1 (es) * | 2006-08-02 | 2011-04-05 | Novartis Ag | PROCEDIMIENTO PARA LA SINTESIS DE UN PEPTIDOMIMETICO DE Smac INHIBIDOR DE IAP, Y COMPUESTOS INTERMEDIARIOS PARA LA SINTESIS DEL MISMO |
-
2010
- 2010-08-11 AU AU2010283748A patent/AU2010283748A1/en not_active Abandoned
- 2010-08-11 MY MYPI2012000350A patent/MY160475A/en unknown
- 2010-08-11 KR KR1020187004166A patent/KR20180020315A/ko not_active Ceased
- 2010-08-11 MX MX2013011692A patent/MX351274B/es unknown
- 2010-08-11 US US13/388,149 patent/US8623385B2/en active Active
- 2010-08-11 RU RU2015155182A patent/RU2671196C1/ru not_active IP Right Cessation
- 2010-08-11 CN CN201080035867.0A patent/CN102471331B/zh not_active Expired - Fee Related
- 2010-08-11 PE PE2017000424A patent/PE20170777A1/es not_active Application Discontinuation
- 2010-08-11 CA CA2769616A patent/CA2769616A1/en not_active Abandoned
- 2010-08-11 BR BR112012003118A patent/BR112012003118A2/pt not_active Application Discontinuation
- 2010-08-11 SG SG2012004222A patent/SG177713A1/en unknown
- 2010-08-11 EP EP10751839A patent/EP2464644A1/en not_active Withdrawn
- 2010-08-11 PE PE2012000206A patent/PE20121132A1/es not_active Application Discontinuation
- 2010-08-11 KR KR1020127006234A patent/KR20120048008A/ko not_active Ceased
- 2010-08-11 JP JP2012524227A patent/JP2013501751A/ja not_active Withdrawn
- 2010-08-11 CN CN201610031620.0A patent/CN105646471A/zh active Pending
- 2010-08-11 IN IN858DEN2012 patent/IN2012DN00858A/en unknown
- 2010-08-11 WO PCT/EP2010/061679 patent/WO2011018474A1/en not_active Ceased
- 2010-08-11 MX MX2012001844A patent/MX2012001844A/es active IP Right Grant
- 2010-08-12 TW TW099126987A patent/TWI607006B/zh not_active IP Right Cessation
- 2010-08-12 AR ARP100102972A patent/AR077869A1/es not_active Application Discontinuation
-
2012
- 2012-01-18 ZA ZA2012/00390A patent/ZA201200390B/en unknown
- 2012-01-19 TN TNP2012000026A patent/TN2012000026A1/en unknown
- 2012-01-26 IL IL217760A patent/IL217760A0/en unknown
- 2012-02-07 MA MA34608A patent/MA33511B1/fr unknown
- 2012-02-09 CO CO12023091A patent/CO6612189A2/es not_active Application Discontinuation
- 2012-02-10 CL CL2012000349A patent/CL2012000349A1/es unknown
-
2013
- 2013-12-03 US US14/095,313 patent/US9540363B2/en not_active Expired - Fee Related
-
2014
- 2014-08-14 AU AU2014213533A patent/AU2014213533A1/en not_active Abandoned
- 2014-08-20 PH PH12014501890A patent/PH12014501890B1/en unknown
-
2016
- 2016-03-24 JP JP2016060543A patent/JP2016179976A/ja not_active Ceased
- 2016-05-13 AU AU2016203145A patent/AU2016203145A1/en not_active Abandoned
- 2016-11-30 US US15/364,841 patent/US10093665B2/en not_active Expired - Fee Related
-
2017
- 2017-11-03 AU AU2017254950A patent/AU2017254950B2/en not_active Ceased
-
2018
- 2018-06-20 JP JP2018116705A patent/JP2018172403A/ja active Pending
- 2018-08-31 US US16/120,073 patent/US20180370960A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL260127B (en) | mek inhibitors and methods of using them | |
| MX350761B (es) | Inhibidores de isoindolinona de fosfatidilinositol 3-cinasa. | |
| MX2010003866A (es) | Heteroaril amidas utiles como inhibidores de canales de sodio dependientes de voltaje. | |
| WO2009114118A3 (en) | Oral pharmaceutical compositions of buprenorphine and method of use | |
| PT1940839E (pt) | Inibidores de piridopirimidinona pi3k alfa | |
| TW200740803A (en) | Heterocyclic derivatives as modulators of ion channels | |
| MX2010003864A (es) | Amidas utiles como inhibidores de canales de sodio dependientes de voltaje. | |
| MY166653A (en) | Derivatives of 1-amino-2-cyclobutylethylboronic acid | |
| MX2010013020A (es) | Metodos y composiciones para trastornos del sueño y otros trastornos. | |
| MY157017A (en) | Sulfonamide derivatives | |
| TN2010000203A1 (en) | Beta-lactamase inhibitors | |
| MX2012001974A (es) | Compuestos de biarilo y metodos de uso de los mismos. | |
| PH12014500053A1 (en) | Proteasome inhibitors | |
| MY150855A (en) | Oral compositions containing extracts of zizyphus joazeiro and related methods | |
| WO2010002956A3 (en) | Heterocyclic derivatives as modulators of ion channels | |
| MX2011013032A (es) | Inhibidores de fosfatidilinositol 3-cinasa. | |
| MX2011011109A (es) | Formulaciones orales de bendamustina. | |
| ECSP12011659A (es) | Formulaciones orales sólidas y formas cristalinas de un inhibidor de la proteína de apoptosis | |
| UA99787C2 (en) | Lactams as beta secretase inhibitors | |
| IL205696A0 (en) | Heterocyclic derivatives, compositions comprising the same and uses thereof | |
| MX2010003563A (es) | Inhibidores de proteina cinasa de c-met. | |
| PH12014501890A1 (en) | Solid oral formulations and crystalline forms of an inhibitor of apoptosis protein | |
| MX2011008645A (es) | Inhibidores de tetrahidrotiazolopiridina de fosfatidilinositol 3 cinasa. | |
| UA106082C2 (uk) | АМІНОПІРАЗОЛ ТРИАЗОЛОТІАДІАЗОЛЬНІ ІНГІБІТОРИ ПРОТЕЇНКІНАЗИ c-МЕТ | |
| MX2011012522A (es) | Inhibidores de pirazol sustituido de proteina cinasa c-met. |